Skip to main content

Applied BioCode, EraGen Reach MDx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Applied BioCode is providing EraGen Biosciences access to its Barcoded Magnetic Bead technology and the CE-marked BioCode -1000 system under a partnership and licensing agreement announced today.

The technology provides a solution for development and clinical laboratory use of multiplexed infectious disease and genetic tests, Applied BioCode said. Its President, Winston Ho, added in a statement that the combination of his firm's technology with EraGen's patented chemistry is expected to result in a "powerful testing platform for clinical laboratories."

Financial and other terms of the deal were not disclosed.

"We look forward to commercializing molecular diagnostics that address not only customers needing real-time molecular testing, but also those in the growing segment that need highly multiplexed in vitro diagnostics," Irene Hrusovsky, chairperson and chief executive of EraGen, added.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.